ArticleNPJ Parkinson's disease2026

Evaluation of c-Abl inhibitor vodobatinib in subjects with early Parkinson's disease: a phase 2, randomized, double-blind, placebo-controlled study.

Harini Sarva et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.